Drug Trial Radar · NCT06479135
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Last checked: Nov 19, 2026Latest source record: Sep 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
Jun 3, 2024
Primary completion
Dec 31, 2026
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Kartos Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 28, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial is evaluating whether addition of navtemadlin to ruxolitinib treatment will provide more clinical benefit than ruxolitinib alone for patients with Myelofibrosis who have a suboptimal response to ruxolitinib treatment alone. Subjects will start by receiving ruxolitinib alone in the run-in period. Those who demostrate a suboptimal response from ruxolitinib alone will then be randomized 2:1 to receive navtemadlin or navtemadlin placebo as add-on treatment to their ongoing ruxolitinib. Randomized means that subjects will be assigned to a group by chance, like a flip of a coin. The study is blinded, meaning the subjects, doctors, central endpoint assessors and sponsor will not know which add on treatment (navtemadlin or navtemadlin placebo) the subject is receiving.
Conditions
- Myelofibrosis
- Post-PV MF
- Post-ET Myelofibrosis
- Primary Myelofibrosis
- MF
Interventions
NavtemadlinDrug
Navtemadlin is an investigational MDM2 inhibitor
Navtemadlin placeboDrug
Navtemadlin placebo
RuxolitinibDrug
Ruxolitinib is a janus kinase 1/2 inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- To compare spleen volume reduction (SVR35) between Arm 1 and Arm 2Time frame: 24 weeks
- To compare total symptom score reduction (TSS50) between Arm 1 and Arm 2Time frame: 24 weeks
Locations
215 sites in 19 countries. Site status is shown where the registry gives one.
UAB Hospital
Birmingham, Alabama · Recruiting
Banner MD Anderson Cancer Center
Gilbert, Arizona · Recruiting
Mayo Clinic - Phoenix
Phoenix, Arizona · Recruiting
UC San Diego Moores Cancer Center
La Jolla, California · Recruiting
UCLA Hematology/Oncology Clinic - Los Angeles
Los Angeles, California · Recruiting
Scripps Health, Prebys Cancer Center
San Diego, California · Recruiting
The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Torrance, California · Recruiting
Rocky Mountain Cancer Centers - Aurora
Aurora, Colorado · Recruiting
Medical Oncology Hematology Consultants, PA
Newark, Delaware · Recruiting
MedStar Georgetown University Hospital, Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia · Recruiting
Mayo Clinic - Jacksonville
Jacksonville, Florida · Recruiting
University of Miami
Miami, Florida · Recruiting
AdventHealth Cancer Institute
Orlando, Florida · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
Mission Cancer + Blood
Des Moines, Iowa · Recruiting
University of Kansas Cancer Center - Westwood
Westwood, Kansas · Recruiting
Norton Cancer Institute
Louisville, Kentucky · Recruiting
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana · Recruiting
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland · Recruiting
The Center for Cancer and Blood Disorders
Bethesda, Maryland · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
University of Michigan Hospital
Ann Arbor, Michigan · Recruiting
Henry Ford Cancer Institute - Brigitte Harris Cancer Pavilion
Detroit, Michigan · Recruiting
Nebraska Hematology - Oncology, P.C.
Lincoln, Nebraska · Recruiting
Mohtaseb Cancer Center and Blood Disorders
Henderson, Nevada · Recruiting
Hackensack University Medical Center
Hackensack, New Jersey · Recruiting
Brookdale University Hospital and Medical Center
Brooklyn, New York · Recruiting
Cayuga Cancer Center
Ithaca, New York · Recruiting
Northwell Health, R.J. Zuckerberg Cancer Center
Lake Success, New York · Recruiting
ICAHN School of Medicine at Mount Sinai
New York, New York · Recruiting
Montefiore Einstein Comprehensive Cancer Center
The Bronx, New York · Recruiting
Medical University of South Carolina (MUSC)
Charleston, North Carolina · Recruiting
Atrium Health Levine Cancer Institute
Charlotte, North Carolina · Recruiting
Duke University Medical Center
Durham, North Carolina · Recruiting
Regional Medical Oncology Center
Wilson, North Carolina · Recruiting
Atrium Health Wake Forest Baptist
Winston-Salem, North Carolina · Recruiting
Gabrail Cancer Center
Canton, Ohio · Recruiting
University of Cincinnati Medical Center
Cincinnati, Ohio · Recruiting
Cleveland Clinic Cancer Center at Fairview Hospital
Cleveland, Ohio · Recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
Showing 40 of 215 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.